Why Choose Duke
Access to Clinical Trials
You may benefit from participating in our clinical trials, which have evaluated a variety of novel therapies, including the effectiveness of certain antioxidants, as well as new diagnostic approaches. As part of the Nonalcoholic Steatohepatitis (NASH) Clinical Research Network, we offer you the opportunity to participate in treatment studies that may test new therapies and help us better understand liver diseases.
National Leaders in Liver Research
You benefit from information collected by us and other researchers that highlight promising treatments. Additionally, the NASH network directs research into treating nonalcoholic fatty liver disease, which is often associated with obesity or a family history of liver disease.
Experts in the Latest Diagnostic Tool
We were involved in the research and development of FibroScan and were one of the first medical centers to offer this noninvasive alternative to liver biopsy. It uses ultrasound to evaluate scarring within the liver, also known as liver fibrosis, which contributes to cirrhosis.